-
EP4347797
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4347797
| EP4347797 - HYPOIMMUNOGENIC CELLS COMPRISING ENGINEERED HLA-E OR HLA-G [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 08.03.2024 Database last updated on 18.11.2024 | |
| Former | The international publication has been made Status updated on 02.12.2022 | ||
| Former | unknown Status updated on 08.07.2022 | Most recent event Tooltip | 02.08.2024 | Change: Validation states | published on 04.09.2024 [2024/36] | 02.08.2024 | Change - extension states | published on 04.09.2024 [2024/36] | Applicant(s) | For all designated states Sana Biotechnology, Inc. 188 East Blaine Street, Suite 400 Seattle, Washinton 98102 / US | [2024/15] | Inventor(s) | 01 /
SCHREPFER, Sonja San Mateo, CA 94080 / US | 02 /
REBAR, Edward San Francisco, CA 94158 / US | [2024/15] | Representative(s) | CMS Cameron McKenna Nabarro Olswang LLP Cannon Place 78 Cannon Street London EC4N 6AF / GB | [2024/15] | Application number, filing date | 22734408.2 | 25.05.2022 | [2024/15] | WO2022US30934 | Priority number, date | US202163194106P | 27.05.2021 Original published format: US 202163194106 P | US202163255912P | 14.10.2021 Original published format: US 202163255912 P | [2024/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022251367 | Date: | 01.12.2022 | Language: | EN | [2022/48] | Type: | A1 Application with search report | No.: | EP4347797 | Date: | 10.04.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.12.2022 takes the place of the publication of the European patent application. | [2024/15] | Search report(s) | International search report - published on: | EP | 01.12.2022 | Classification | IPC: | C12N5/10, C07K14/705 | [2024/15] | CPC: |
C12N5/0636 (EP,IL,KR,US);
A61K39/4611 (KR);
A61K39/4613 (EP,IL,US);
A61K39/4631 (KR);
A61K39/4644 (KR);
A61K39/464429 (EP,IL,US);
A61P35/00 (KR);
C07K14/4747 (US);
C07K14/7051 (KR);
C07K14/70532 (KR);
C07K14/70539 (KR,US);
C07K16/2803 (KR);
C07K16/2878 (KR);
C07K16/2887 (KR);
C12N15/11 (US);
C12N15/907 (US);
C12N9/22 (US);
C12N2310/20 (KR,US);
C12N2501/48 (EP,IL);
C12N2501/50 (EP,IL);
C12N2510/00 (EP,IL,KR,US);
C12N2800/80 (US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/15] | Title | German: | HYPOIMMUNOGENE ZELLEN MIT MANIPULIERTEM HLA-E ODER HLA-G | [2024/15] | English: | HYPOIMMUNOGENIC CELLS COMPRISING ENGINEERED HLA-E OR HLA-G | [2024/15] | French: | CELLULES HYPOIMMUNOGÈNES COMPRENANT HLA-E OU HLA-G GÉNÉTIQUEMENT MODIFIÉS | [2024/15] | Entry into regional phase | 20.12.2023 | National basic fee paid | 20.12.2023 | Designation fee(s) paid | 20.12.2023 | Examination fee paid | Examination procedure | 20.12.2023 | Examination requested [2024/15] | 20.12.2023 | Date on which the examining division has become responsible | 10.07.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 28.03.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI]US2007036773 (COOPER LAURENCE [US], et al); | [XI]WO2020117852 (RUBIUS THERAPEUTICS INC [US]); | [XI]WO2020118447 (SINAI HEALTH SYS [CA]); | [XI]WO2020168317 (HARVARD COLLEGE [US]); | [XI]US2021015859 (VALAMEHR BAHRAM [US], et al); | [XI]WO2021041316 (SANA BIOTECHNOLOGY INC [US]); | [XI]WO2021044379 (CRISPR THERAPEUTICS AG [CH]); | [XI]WO2021055985 (CELLERANT THERAPEUTICS INC [US]); | [I]WO2021072302 (NEW YORK STEM CELL FOUND INC [US], et al); | [E]WO2022113056 (CRISPR THERAPEUTICS AG [CH]) | by applicant | GB2211504 | US5420032 | WO9715664 | US5674722 | WO9853058 | WO9853059 | WO9853060 | US6140081 | WO0216536 | US6453242 | US6503717 | WO03016496 | US6534261 | US2003077249 | US6599692 | US6689558 | US6794136 | US6833252 | US2005064474 | US2005267061 | US7030215 | US7067317 | US7070934 | US2007117128 | US7253273 | US7262054 | US2007218528 | US7355012 | US7361635 | US7452718 | US7541034 | US7579188 | US7595194 | US7674620 | WO2010104949 | WO2010144696 | US7897389 | US7982011 | US2011301073 | WO2012079000 | US8206699 | US8227247 | US8252586 | US8263402 | US8273570 | WO2012138927 | WO2012163805 | WO2013040557 | US2013253040 | US8927280 | US9057053 | US9062289 | US9157062 | US9193951 | WO2016030414 | US2016068814 | US2016115448 | US9376664 | WO2016126608 | WO2016149578 | US9458428 | US9487752 | WO2016183041 | US2016348073 | US2016362661 | US2017002325 | US2017058263 | WO2017058753 | WO2017058850 | US2017152485 | US9683215 | US2017183627 | US2017182097 | US2017198255 | US9709553 | US2017253856 | WO2017172976 | US9850463 | US9862925 | WO2018028647 | US9968637 | WO2018093681 | US2018187148 | WO2018132783 | US2018236004 | WO2018176390 | US10093897 | WO2018213337 | WO2019006072 | US10233422 | WO2020014482 | WO2020018615 | WO2020018620 | US2020246381 | WO2020168317 | US2020339699 | US11026975 | US19900630161 | US19600630523 | WO2020US44635 | WO2021US29443 |